Global Mucopolysaccharidosis Type IV Epiomic Epidemiology Report 2018 - Forecast In 28 Major Markets to 2028

DUBLIN, May 11, 2018 /PRNewswire/ --

The "Epiomic Epidemiology Series: Mucopolysaccharidosis Type IV Forecast In 28 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is an inherited autosomal recessive genetic disorder in which glycosaminoglycans (GAGs) are accumulated in lysosomes due to mutations that cause loss of function of an enzyme responsible for degrading GAGs. The disorder manifests with multiple skeletal defects and has two subtypes, MPS IVA and MPS IVB, differing in the mutated gene. MPS IV constitutes a burden to the patients and their families as the disease progresses and the patients develop mobility impairment, breathing problems and corneal clouding.

This report provides the current prevalent population for MPS IV across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Switzerland, Ireland, Portugal, Czech Republic, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

MPS IV patients grouped by disease subtype, history of surgical procedures and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of MPS IV include:

• Recurrent upper respiratory tract infections
• Sleep apnoea
• Pulmonary hypertension
• Osteoporosis
• Inguinal hernia
• Hepatomegaly
• Dental caries
• Vision impairment
• Hearing impairment and loss
• Disturbances in urinary function
  

Key Topics Covered:

1. List Of Tables And Figures

2. Introduction

3. Cause Of The Disease

4. Risk Factors & Prevention

5. Diagnosis Of The Disease

6. Variation By Geography/Ethnicity

7. Disease Prognosis & Clinical Course

8. Key Comorbid Conditions / Features Associated With The Disease

9. Methodology For Quantification Of Patient Numbers

10. Top-Line Prevalence For Mucopolysaccharidosis Type IV

11. Features Of Mucopolysaccharidosis Type IV Patients

12. MPS IVA

13. History Of Surgical Procedures In MPS IVA Patients

14. Comorbidities Of MPS IVA Patients

15. Abbreviations Used In The Report

16. Reports & Publications

17. Online Epidemiology Databases

18. Online Pharmaceutical Pricing Database

19. References

20. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2ddnlk/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-mucopolysaccharidosis-type-iv-epiomic-epidemiology-report-2018---forecast-in-28-major-markets-to-2028-300647128.html

SOURCE Research and Markets